A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.


Updates from The Motley Fool

Latest updates on BioCryst Pharmaceuticals from Fool.com.


Stock Performance

BCRX vs. S&P 500 | 2 Year Performance
View Interactive BCRX Charts
Sponsored by

Key Data Points

Primary metrics and data points about BioCryst Pharmaceuticals.
Current Price: $4.13
Prev Close: $4.15
Open: $4.15
Bid: $4.00
Ask: $4.26
Day's Range: $4.11 - $4.25
52wk Range: $1.63 - $14.00
Volume: 334,333
Avg Vol 1,311,840
Market Cap: $302.88M
P/E (ttm): -4.23
EPS (ttm): -$0.98
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about BioCryst Pharmaceuticals.
CAPS Rating 2 out of 5
 
253 Outperform
84 Underperform
CAPS All Stars
 
45 Outperform
29 Underperform

How do you think BioCryst Pharmaceuticals will perform against the market?



You pick for BioCryst Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Jon P. Stonehouse, CEO

100% Approve

Based on 1 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for BioCryst Pharmaceuticals.

A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers